Novan Announces Closing of $40 Million Public Offering of Common Stock
June 21, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 21, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the closing of the Company's previously announced underwritten public offering...
Novan Announces Pricing of $40 Million Public Offering of Common Stock
June 17, 2021 09:00 ET
|
Novan, Inc.
DURHAM, N.C., June 17, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company" or "Novan") (NASDAQ:NOVN) today announced the pricing of the Company's previously announced underwritten public offering...
Novan Announces Proposed Public Offering of Common Stock
June 16, 2021 16:01 ET
|
Novan, Inc.
DURHAM, N.C., June 16, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (the “Company” or “Novan”) (NASDAQ: NOVN) today announced a proposed underwritten public offering of its common stock (the “Offering”)....
Results from Novan’s Exploratory Studies Further Demonstrate Antimicrobial Effect of NITRICIL™ Platform Technology with NVN4100 in Companion Animal Health
June 07, 2021 08:30 ET
|
Novan, Inc.
– Positive in vitro results demonstrate antimicrobial effect of NVN4100 against a wide variety of bacteria and suggest a promising bactericidal mode of action – – Novel in vivo canine pyoderma model...
Novan Announces 1-for-10 Reverse Stock Split
May 25, 2021 08:00 ET
|
Novan, Inc.
DURHAM, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it has filed a Certificate of Amendment to the Restated Certificate of...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
April 22, 2021 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that data from the Company’s previously completed Phase 3 trials of SB206...
Novan Provides Enrollment Update and Announces New Corporate Headquarters
January 19, 2021 09:00 ET
|
Novan, Inc.
– B-SIMPLE4 pivotal Phase 3 study in molluscum contagiosum reaches 90% enrollment with topline data targeted for Q2 2021 – – Company secures new location to serve as corporate headquarters and to...
Novan Exceeds 60% Enrollment in B-SIMPLE4 Pivotal Phase 3 Study of SB206 for Treatment of Molluscum
December 15, 2020 09:00 ET
|
Novan, Inc.
– Completion of patient enrollment targeted for Q1 2021 with readout of topline results targeted for Q2 2021 – – SB206, if approved, has the potential to meet an important need for the treatment of...
Novan Receives Approval to Transfer to Nasdaq Capital Market
November 04, 2020 07:30 ET
|
Novan, Inc.
– Trading on Nasdaq Capital Market is expected to begin on November 5, 2020 – – Company receives additional 180-day grace period, until May 3, 2021, to satisfy the $1.00 bid price requirement to...
Novan to Present at the Virtual Investor KOL Roundtable
October 21, 2020 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Oct. 21, 2020 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that members of management will participate in the Virtual Investor KOL...